Vir Biotechnology, Inc. (Nasdaq: VIR) CEO Marianne De Backer will participate in a fireside chat at the BofA Securities Healthcare Conference 2024 on May 14. The event will be live webcasted and archived on the Vir website.
Marianne De Backer, CEO di Vir Biotechnology, Inc. (Nasdaq: VIR), parteciperà a un colloquio informale durante la Conferenza Sanitaria di BofA Securities 2024 il 14 maggio. L'evento sarà trasmesso in diretta e archiviato sul sito web di Vir.
Marianne De Backer, CEO de Vir Biotechnology, Inc. (Nasdaq: VIR), participará en una charla informal en la Conferencia de Salud de BofA Securities 2024 el 14 de mayo. El evento se retransmitirá en vivo y se archivará en el sitio web de Vir.
Marrianne De Backer 대표이사 인 Vir Biotechnology, Inc. (Nasdaq: VIR)은 5월 14일에 열리는 2024년 BofA 증권 헬스케어 컨퍼런스에서 패널토의에 참여할 예정입니다. 이 행사는 실시간 웹캐스트로 진행되며 Vir 웹사이트에 아카이브될 예정입니다.
Marianne De Backer, PDG de Vir Biotechnology, Inc. (Nasdaq: VIR), participera à un entretien décontracté lors de la Conférence sur la Santé de BofA Securities 2024 le 14 mai. L'événement sera diffusé en direct et archivé sur le site web de Vir.
Marianne De Backer, CEO von Vir Biotechnology, Inc. (Nasdaq: VIR), wird am 14. Mai 2024 an einem Fireside Chat während der BofA Securities Gesundheitskonferenz teilnehmen. Das Ereignis wird live übertragen und auf der Webseite von Vir archiviert.
Positive
None.
Negative
None.
SAN FRANCISCO--(BUSINESS WIRE)--
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer is scheduled to participate in a fireside chat at the BofA Securities Healthcare Conference 2024 on Tuesday, May 14, at 4:20 p.m. PT / 7:20 p.m. ET.
A live webcast of the fireside chat will be made available under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there for 30 days.
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. is an immunology company focused on powering the immune system to transform lives by treating and preventing infectious diseases and other serious conditions, including viral-associated diseases. Vir has assembled two technology platforms that are designed to modulate the immune system by exploiting critical observations of natural immune processes. Its current clinical development pipeline consists of product candidates targeting hepatitis delta and hepatitis B viruses and human immunodeficiency virus. Vir has several preclinical candidates in its pipeline, including those targeting influenza A and B, COVID-19, RSV/MPV and HPV. Vir routinely posts information that may be important to investors on its website.
When will Marianne De Backer participate in the BofA Securities Healthcare Conference 2024?
Marianne De Backer will participate on Tuesday, May 14, at 4:20 p.m. PT / 7:20 p.m. ET.
Where can I watch the live webcast of the fireside chat?
The live webcast will be available under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived for 30 days.
An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.